Quantcast

Industry news that matters to you.  Learn more

New Publication from Major UK Prospective Screening Trial for Ovarian Cancer Reaffirms High Performance Characteristics of ROCA

Abcodia, a specialist company engaged in the development of tests for the early detection of cancer, with exclusive worldwide licence to the ovarian cancer screening test, ROCA®, has welcomed the publication of a major study that reaffirms its high performance.

Improved Survival of Ovarian Cancer Patients Receiving Treatment Guided by Comprehensive Tumour Profiling

Data from an ovarian cancer registry presented at the European Society for Gynaecological Oncology (ESGO) annual meeting reinforce comprehensive tumour profiling as a ‘game changer’ for oncologists.

Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform

Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), recently announced that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications.  Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions.  ESI develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.

Almac Validates Novel Test for Ovarian Cancer Patients

Almac Group Ltd.’s Diagnostics Business Unit recently announced the validated results of the ALM AADx assay, a gene expression test that identifies a subgroup of high grade serous ovarian cancer (HGSOC) patients that have a good prognosis following standard of care chemotherapy.

Biocartis and VIB Join Forces to Develop Unique Diagnostic Cancer Test

Biocartis and VIB recently announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC). This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply and rapidly be detected by Biocartis’ molecular diagnostics platform Idylla™.